The Latvian Saeima's Social Affairs and Labor Committee recently endorsed a proposal to implement immunization against respiratory syncytial virus (RSV) for newborns, leveraging long-acting monoclonal antibodies. This initiative aims to protect infants from severe RSV infections, which can occur predominantly in the initial months after birth. The plan includes providing immunity for the entire season with just one dose, highlighting the need for effective preventive measures as RSV can pose serious health risks to infants.

Renāte Snipe, the administrative director of the Children’s Clinical University Hospital and a board member of the Latvian Pediatric Association, presented evidence during the committee meeting demonstrating the potential severity of RSV infections in newborns, prompting the push for an immunization program. As part of the initial proposal, the committee seeks to secure funding to vaccinate all newborns born during the RSV season, in addition to those children under 19 months with significant chronic health issues, underscoring the program's inclusive approach to safeguarding vulnerable populations.

Estimates suggest that if the birth rate remains consistent with 2025 levels, around 5,000 to 6,000 children would require this preventive measure. This initiative reflects a commitment to enhancing public health in Latvia, especially at a time when respiratory viruses can significantly impact young lives, ultimately aiming to reduce hospitalizations and improve overall healthcare outcomes for new parents and their infants.